Publikationen der dach

Publikationen der D-A-CH MDS Gruppe 2002 bis 2012 2002 1) Aivado M, Rong A; Stadler M, Germing U, Giagounidis A, Strupp C, Novotny J, Josten KM, Kobbe G, Hildebrandt B, Gattermann N, Aul C, Haas R, Ganser A. Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cel s. Eur J of Haematol 2002, 68, 210-216 2) Seipelt G, Germing U, Koschmieder S, Böhme A, Aul C, Hoelzer D. Secondary acute myeloid leukaemia with monosomy 7 in identical adult twins. Br J Haematol. 2002;116(2):338-40 3) Aul C, Giagounidis A, Germing U, Ganser A. Myelodysplastic syndromes. Diagnosis and therapeutic strategies. Med Klin 2002 Nov 15;97(11):666-76. Review. 4) Aul C, Giagounidis A, Germing U, Ganser A. Evaluating the prognosis of patients with myelodysplastic syndromes. Ann Hematol. 2002 Sep;81(9):485-97. Review. 5) Kaeferstein A, Krug U, Tiesmeier J, Aivado M, Faulhaber M, Stadler M, Krauter J, Germing U, Hofmann WK, Koeffler HP, Ganser A, Verbeek W. The emergence of a C/EBPalpha mutation in the clonal evolution of MDS towards secondary AML. Leukemia. 2003 ;17(2):343-9 6) Stadler M, Germing U, Kliche KO, Josten KM, Kuse R, Hofmann WK, Schrezenmeier H, Novotny J, Anders O, Eimermacher H, Verbeek W, Kreipe HH, Heimpel H, Aul C, Ganser A: A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes Leukemia 2004, 18, 460-465 7) Aul C, Giagounidis A, Heinsch M, Germing U, Ganser A. Prognostic indicators and scoring systems for predicting outcome in patients with myelodysplastic syndromes. Rev Clin Exp Hematol. 2004 Dec 1;8(2):E1. Review 8) Giagounidis AA, Germing U, Wainscoat JS, Boultwood J, Aul C. The 5q- syndrome. Hematology. 2004 Aug;9(4):271-7. 9) Germing U, Strupp C, Kündgen A, Bowen D, Aul C, Haas R, Gattermann N. No increase in age-specific incidence of myelodysplastic syndromes. Haematologica. 2004 Aug;89(8):905-10. 10) Steidl C, Steffens R, Gassmann W, Hildebrandt B, Hilgers R, Germing U Haase D. Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patients. Leuk Res. 2005; 29(9): 987-93 11) Germing U, Hildebrandt B, Pfeilstocker M, Nosslinger T, Valent P, Fonatsch C, Lubbert M, Haase D, Steidl C, Krieger O, Stauder R, Giagounidis AA, Strupp C, Kundgen A, Muel er T, Haas R, Gattermann N, Aul C. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 2005; 19(12):2223-31 12) Giagounidis AAN, Haase S, Germing U, Schlegelberger B, Wilkens L, Büsche
G, Kreipe HH, Wysk J, Grips KH, Grabenhorst U, Rothmann F, Lübbert M,
Ganser A, Aivado M, Heinsch M, Aul C: Treatment of myelodysplastic
syndrome with isolated del(5q) including bands q31-q33 with a combination of
all-trans-retinoic acid and tocopherol-alpha: a phase II study Annals of
Hematology 2005, 84, 389-394
13) Pitako, JA; Haas, PS; Van den Bosch, J, Müller-Berndorff H, Kündgen A,
Germing U, Wijermans PW, Lübbert M: Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine: Ann Hematol 2005,84, 25-31 14) Giagounidis AA, Germing U, Strupp C, Hildebrandt B, Heinsch M, Aul C. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup.An Hematol. 2005 Sep;84(9):569-71. 15) Giagounidis AA, Haase S, Germing U, Heinsch M, Aul C. Autoimmune disorders in two patients with myelodysplastic syndrome and 5q deletion. Acta Haematol. 2005;113(2):146-148 16) Platzbecker U, Germing U, Schäkel U, Il mer T, Soucek S, Schaich M, Ehninger G, Thiede C: Association with the single-nucleotide polymorphim (Glu785Lys) of the G-CSF receptor with high-risk MDS and AML with multilineage dysplasia. Leukemia, 2006, Dec; 20(12): 2188-9 17) Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, Germing U, Haas R, Dohner H, Gattermann N: The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with al -trans retinoic acid in patients with acute myeloid leukemia. Cancer. 2006; 1; 106(1):112-9. 18) Giagounidis AA, Germing U, Aul C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res. 2006 Jan 1;12(1):5-10. Review. 19) Germing U, Platzbecker U, Giagounidis A, Aul C: Platelet morphology, platelet mass, platelet count and prognosis in patients with myelodysplastic syndromes. Brit J Haemat 2007, 138, 399-400 20) Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Kundgen A, Lübbert M, Kunzmann R, Giagounidis AAN, Aul C, Trümper L, Krieger O, Stauder R, Mül er TH, Wimazal F, Valent P, Fonatsch C, Steidl C: New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007 Dec;110(13):4385 – 4395 21) Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, Haferlach T, Haase D, Kolb HJ, Krieger O, Loken M, van de Loosdrecht A, Ogata K, Orfao A, Pfeilstöcker M, Rüter B, Sperr WR, Stauder R, Wel s DA. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res. 2007; 31(6):727-36 22) Giagounidis AA, Germing U, Haase S, Aul C. Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes. Ther Clin Risk Manag. 2007 Aug;3(4):553-62 23) Germing U, Strupp C, Knipp S, Kuendgen A, Giagounidis A, Hildebrandt B, Aul C, Haas R, Gattermann N, Bennett JM. Chronic myelomonocytic leukemia in the light of the WHO proposals. Haematologica. 2007 Jul;92(7):974-7 24) Knipp S, Hildebrand B, Kündgen A, Giagounidis A, Kobbe G, Haas R, Aul C, Gattermann N, Germing U. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer. 2007,15;110(2):345-52. 25) Gattermann N, Hofmann WK, Meessen A, Schmitz S, Tsamaloukas A, Vol mer T, Wedding U, Plesnila-Frank C, Schramm W, Berger K. Myelodysplastic syndromes: aspects of current medical care and economic considerations in Germany. Onkologie. 2008 Sep;31(8-9):477-84. 26) Knipp S, Strupp C, Gattermann N, Hildebrandt B, Schapira M, Giagounidis A, Aul C, Haas R, Germing U. Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome. Leuk Res. 2008; 32(1):33-37 27) Platzbecker U, Bornhauser M, Germing U, Stumpf J, Scott BL, Kröger N, Schwerdtfeger R, Böhm A, Kobbe G, Theuser C, Rabitsch W, Valent P, Sorror ML, Ehninger G, Deeg HJ. Red Blood Cel Transfusion Dependence and Outcome after Allogeneic Peripheral Blood Stem Cel Transplantation in Patients with de Novo Myelodysplastic Syndrome (MDS) Biology of blood and Marrow Transplantation 2008, 14 1217-1225 28) Giagounidis A, Fenaux P, Mufti GJ, Muus P, Platzbecker U, Sanz G, Cripe L,
Von Lilienfeld-Toal M, Wel s RA. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol. 2008 May;87(5):345-52. Epub 2008 Feb 12. Review. 29) Neukirchen J, Blum S, Kuendgen A, Strupp C, Aivado M, Haas R, Aul C, Gattermann N, Germing U. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes. Eur J Haematol. 2009 Nov;83(5):477-82. 30) Valent P, Hofmann WK, Büsche G, Sotlar K, Horny HP, Haase D, Haferlach T, Kern W, Bettelheim P, Baumgartner C, Sperr WR, Nösslinger T, Wimazal F, Giagounidis AA, Lübbert M, Krieger O, Kolb HJ, Stauder R, Pfeilstöcker M, Gattermann N, Fonatsch C, Aul C, Germing U: Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes. Ann Hematol. 2009 Jul;88(7):607-11. 31) van de Loosdrecht AA, Alhan C, Béné MC, Del a Porta MG, Dräger AM, Feuil ard J, Font P, Germing U, Haase D, Homburg CH, Ireland R, Jansen JH, Kern W, Malcovati L, Te Marvelde JG, Mufti GJ, Ogata K, Orfao A, Ossenkoppele GJ, Porwit A, Preijers FW, Richards SJ, Schuurhuis GJ, Subirá D, Valent P, van der Velden VH, Vyas P, Westra AH, de Witte TM, Wel s DA, Loken MR, Westers TM. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica. 2009 Aug;94(8):1124-34. 32) Platzbecker U, Aul C, Ehninger G, Giagounidis A. Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil. Ann Hematol. 2010 Apr;89(4):427-8. 33) Fenaux P, Bowen D, Gattermann N, Hel ström-Lindberg E, Hofmann WK, Pfeilstöcker M, Sanz G, Santini V: Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. Leuk Res. 2010 Nov; 34(11):1410-6. 34) Goetze K, Platzbecker U, Giagounidis AAN, Haase D, Luebbert M, Aul C, Ganser A, Germing U, Hofmann WK: Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group. Annals of Hematology. 2010 Sep;98(9):841-850 35) Gattermann N, Finel i C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, Schmid M, Taylor K, Vassilieff D, Habr D, Domokos G, Roubert B, Rose C; EPIC study investigators: Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leuk Res. 2010 Sep; 34(9):1143-50. 36) Czibere A, Bruns I, Kröger N, Platzbecker U, Lind J, Zohren F, Fenk R, Germing U, Schröder T, Gräf T, Haas R, Kobbe G: 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after al o-SCT: a retrospective analysis. Bone Marrow Transplant. 2010 May; 45(5):872-6. 37) Noesslinger T, Tüchler H, Germing U, Sperr WR, Krieger O, Haase D, Lübbert M, Stauder R, Giagounidis A, Valent P, Pfeilstöcker M: Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Annals of Oncology. 2010 Jan;21(1):120-125. 38) Wimazal, F; Germing, U; Kundi, M, Noesslinger T, Blum S, Geissler P, Baumgartner C, Pfeilstoecker M, Valent P, Sperr WR: Evaluation of the Prognostic Significance of Eosinophilia and Basophilia in a larger Cohort of Patients with Myelodysplastic Syndromes. Cancer 2010 116, 10 2372-2381 39) Aul C, Giagounidis A, Germing U. Myelodysplastic syndromes. Internist, 2010 40) Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Sel eslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW: Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011 20;29(15):1987-96 41) Passweg JR, Giagounidis AA, Simcock M, Aul C, Dobbelstein C, Stadler M, Ossenkoppele G, Hofmann WK, Schil ing K, Tichel i A, Ganser A. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. J Clin Oncol. 2011 Jan 20;29(3):303-9. Epub 2010 Dec 13 42) Kuendgen A, Bug G, Ottmann O, Haase D, Schanz J, Hildebrandt B, Nachtkamp K, Neukirchen J, Dienst A, Haas R, Germing U, Gattermann N. Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid. Clin Epigenet (2011) 2:389–399 43) Mallo M, Cervera J, Schanz J, Such E, García-Manero G, Luño E, Steidl C, Espinet B, Val espí T, Germing U, Blum S, Ohyashiki K, Grau J, Pfeilstöcker M, Hernández JM, Noesslinger T, Giagounidis A, Aul C, Calasanz MJ, Martín ML, Valent P, Collado R, Haferlach C, Fonatsch C, Lübbert M, Stauder R, Hildebrandt B, Krieger O, Pedro C, Arenil as L, Sanz MÁ, Valencia A, Florensa L, Sanz GF, Haase D, Solé F.: Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia. 2011 Jan;25(1):110-20. 44) Schanz J, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Tuechler H, Valent P, Hildebrandt B, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Kantarjian H, Germing U, Haase D, Estey E.: Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol. 2011;20;29(15):1963-70 45) Loeffler-Ragg J, Germing U, Sperr WR, Herrmann H, Zwierzina H, Valent P, Ulmer H, Stauder R: Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes. Crit Rev Oncol Hematol. 2011, 78(2):150-61. 46) Giagounidis A, Kulasekararaj A, Germing U, Radkowski R, Haase S, Petersen P, Göhring G, Büsche G, Aul C, Mufti GH, Platzbecker U: Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide. Leukemia. 2011 Sep 30. doi: 10.1038/leu.2011.268. 47) Platzbecker U, Santini V, Mufti GJ, Haferlach C, Maciejewski JP, Park S, Solé F, van de Loosdrecht AA, Haase D. Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): consensus statements and report from an expert workshop Leuk Res. 2012 Mar;36(3):264-70. Epub 2011 Dec 3. Review 48) Schroeder T, Kuendgen A, Kayser S, Kröger N, Braulke F, Platzbecker U, Klärner V, Zohren F, Haase D, Stadler M, Schlenk R, Czibere AG, Bruns I, Fenk R, Gattermann N, Haas R, Kobbe G, Germing U. Therapy-related myeloid neoplasms fol owing treatment with radioiodine. Haematologica. 2012 Feb;97(2):206-12 49) Schanz J, Tüchler H, Solé F, Mal o M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D. New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. J Clin Oncol. 2012 Feb 13 50) Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenaux P, Kelaidi C, Pfeilstöcker M, Nösslinger T, Sekeres M, Maciejewski J, Haase D, Schanz J, Seymour J, Kenealy M, Weide R, Lübbert M, Platzbecker U, Valent P, Götze K, Stauder R, Blum S, Kreuzer KA, Schlenk R, Ganser A, Hofmann WK, Aul C, Krieger O, Kündgen A, Haas R, Hasford J, Giagounidis A: Survival, Prognostic Factors, and Rates of LeukemicTransformation in 381 Untreated Patients with MDS and del(5q):A Multicenter Study. Leukemia. 2012 Jan 13. doi: 10.1038/leu.2011.391. [ 51) Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A, Galonska L, Kondakci M, Weigelt C, Fenk R, Germing U, Haas R, Kobbe G. Upfront Al ogeneic Blood Stem Cel Transplantation for Patients with High-Risk Myelodysplastic Syndrome or Secondary Acute Myeloid Leukemia Using a FLAMSA-Based High-Dose Sequential Conditioning Regimen. Biol Blood Marrow Transplant. 2012 Mar;18(3):466-72. 52) Westers TM, Ireland R, Kern W, Alhan C, Bal eisen JS, Bettelheim P, Burbury K, Cullen M, Cutler JA, Del a Porta MG, Dräger AM, Feuil ard J, Font P, Germing U, Haase D, Johansson U, Kordasti S, Loken MR, Malcovati L, Te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Ogata K, Orfao A, Porwit A, Psarra K, Richards SJ, Subirá D, Tindel V, Val espi T, Valent P, van der Velden VH, de Witte TM, Wel s DA, Zettl F, Béné MC, van de Loosdrecht AA. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European leukemianet working group. Leukemia. 2012 Feb 6. doi: 10.1038/leu.2012.30 53) Platzbecker U, Santini V, Mufti GJ, Haferlach C, Maciejewski JP, Park S, Solé F, van de Loosdrecht AA, Haase D. Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): consensus statements and report from an expert workshop. Leuk Res. 2012 Mar;36(3):264-70. Epub 2011 Dec 3. Review

Source: http://www.mds-register.de/wp-content/uploads/Publikationen_der_DACH_MDS-Gruppe.pdf